galcanezumab-gnlm

FDA Drug Profile — EMGALITY

Drug Details

Generic Name
galcanezumab-gnlm
Brand Names
EMGALITY
Application Number
BLA761063
Sponsor
Eli Lilly and Company
NDC Codes
6
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
GALCANEZUMAB

Indications and Usage

1 INDICATIONS AND USAGE EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.